Fair enough, Ant’, but we’re not talking about a $50 supplement here.  This was about AAV mediated reexpression of Yamanaka factors, which would be comparable in complexity to AAV mediated SMA treatment.The point of the post was to illustrate the cost differential of somewhere in the order of 6 powers of 10 once these treatments are no longer “niche products”, but now effectively everyone becomes eligible.Medicine has reached the ceiling of what it can pay for.

Fair enough, Ant’, but we’re not talking about a $50 supplement here.  This was about AAV mediated reexpression of Yamanaka factors, which would be comparable in complexity to AAV mediated SMA treatment.The point of the post was to illustrate the cost differential of somewhere in the order of 6 powers of 10 once these treatments are no longer “niche products”, but now effectively everyone becomes eligible.Medicine has reached the ceiling of what it can pay for.

user
yes
assistant